(Q37205578)

18 August 2017

Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells (English)

1 reference

18 August 2017

1 reference

1 reference

10

Gabriel N Hortobagyi

1 reference

18 August 2017

Satoshi Nakayama

1

1 reference

18 August 2017

Yasuhiro Torikoshi

2

1 reference

18 August 2017

Takeshi Takahashi

3

1 reference

18 August 2017

Tomokazu Yoshida

4

1 reference

18 August 2017

Tamotsu Sudo

5

1 reference

18 August 2017

Tomoko Matsushima

6

1 reference

18 August 2017

Yuko Kawasaki

7

1 reference

18 August 2017

Aya Katayama

8

1 reference

18 August 2017

Keigo Gohda

9

1 reference

18 August 2017

Shinzaburo Noguchi

11

1 reference

18 August 2017

Toshiyuki Sakai

12

1 reference

18 August 2017

Hideki Ishihara

13

1 reference

18 August 2017

Naoto T Ueno

14

1 reference

18 August 2017

24 February 2009

1 reference

18 August 2017

Breast Cancer Research

1 reference

18 August 2017

11

1 reference

18 August 2017

1

1 reference

18 August 2017

R12

1 reference

https://scigraph.springernature.com/pub.10.1186/bcr2231

18 August 2017

0 references

cites work

Prognostic value of proliferation in invasive breast cancer: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Mitotic kinases as regulators of cell division and its checkpoints

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Paclitaxel-induced cell death: where the cell cycle and apoptosis come together

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Cyclin-dependent kinases: engines, clocks, and microprocessors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Role of microtubules in the distribution of the Golgi apparatus: effect of taxol and microinjected anti-alpha-tubulin antibodies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Estrogen receptor expression and sensitivity to paclitaxel in breast cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

A new cancer diagnostic system based on a CDK profiling technology

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687717

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FBCR2231

Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer

21 January 2018

1 reference

12 December 2020

Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide

1 reference

12 December 2020

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

12 December 2020

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

12 December 2020

Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells

1 reference

12 December 2020

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol

1 reference

12 December 2020

Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel

1 reference

12 December 2020

Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation

1 reference

12 December 2020

Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer

1 reference

12 December 2020

Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1186/BCR2231

1 reference

Dimensions Publication ID

18 August 2017

0 references

1 reference

18 August 2017

PubMed publication ID

19239702

1 reference